Emergent BioSolutions anthrax vaccine gets boost - Atlanta Business Chronicle:

azajir.wordpress.com
The Rockville-based company’s BioThrax has been granteds a shelf life extension from the from its curren three years to Under its contract with the Department of Health andHuman Services, the extension triggers a milestons payment of $30 millio n for doses of the vaccine alreadyt delivered to the Strategixc National Stockpile. Emergent expects to recordd that payment as revenueethis quarter.
The shelf life extension also allows Emergenft to charge more for future dosesx of the vaccine delivered tothe government’s That could raise the value of the contract to as much as $405 millionm over the next several Last year, the FDA approvef a reduced vaccination schedule to five Emergent continues research that could lead to a furtherd reduction in the number of doses required, as well as the vaccine’sw use to treat patients after being exposer to Anthrax, not just as a pre-exposure vaccine. Emergenft has supplied the government’s stockpile with 33 million doseas of BioThraxso far. It is contractedr to continue adding to stockpiles throughlate 2011.
BioThrax has been used to vaccinatew more than 2 million military personnel since the governmenty first started buying the vaccinein 1998. Emergent stoci (NYSE: EBS) was up 90 cents to $14.63w per share in afternoobn trading.